XML 29 R11.htm IDEA: XBRL DOCUMENT
v3.25.1

Licensed Rights and Other Intangible Assets | 12 Months Ended
--- | ---
Dec. 31, 2024
Licensed Rights and Other Intangible Assets [Abstract] |
Licensed rights and other intangible assets | 4. Licensed rights and other intangible assets The following provides information about our license rights and other intangible assets, net (in thousands):
|  | As of December 31, 2024 |  |  | As of December 31, 2023 |
|  | Gross |  |  |  |  |  |  |  |  | Gross |  |  |  |  |  |  |
|  | Carrying |  |  | Accumulated |  |  |  |  |  | Carrying |  |  | Accumulated |  |  |  |
|  | Amount |  |  | Amortization |  |  | Net |  |  | Amount |  |  | Amortization |  |  | Net |
Intangible assets subject to amortization: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Hormone therapy drug patents |  | $ | 5,766 |  |  | $ | 2,058 |  |  | $ | 3,708 |  |  | $ | 6,818 |  |  | $ | 1,871 |  |  | $ | 4,947 |
Hormone therapy drug patents applied and pending approval |  |  | 304 |  |  |  | — |  |  |  | 304 |  |  |  | 842 |  |  |  | — |  |  |  | 842 |
Intangible assets subject to amortization |  |  | 6,070 |  |  |  | 2,058 |  |  |  | 4,012 |  |  |  | 7,660 |  |  |  | 1,871 |  |  |  | 5,789 |
Intangible assets not subject to amortization: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trademarks/trade name rights |  |  | 309 |  |  |  | — |  |  |  | 309 |  |  |  | 309 |  |  |  | — |  |  |  | 309 |
Intangible assets, net |  | $ | 6,379 |  |  | $ | 2,058 |  |  | $ | 4,321 |  |  | $ | 7,969 |  |  | $ | 1,871 |  |  | $ | 6,098 |
We recorded, in continuing operations, amortization expense related to patents of $509.1 thousand for 2024 and $844.2 thousand for 2023, of which $483.5 thousand is accelerated amortization as a result of a review of our intangible assets. The Company conducts regular reviews of the individual patents and portfolios. As a result of this review and also based on input from its licensing partners, in the three months ended June 30, 2024 the Company determined it had an indicator of impairment, as it had abandoned the legal right and title to a portion of its granted patent portfolio and had ceased pursuit of a portion of its pending patents based on input from its licensing partners. The Company recognized an impairment loss of $1,268 thousand related to those abandoned patents and applications, which is classified as an impairment of long-lived assets on the Company’s consolidated statements of operations for the twelve months ended December 31, 2024. In the year ending December 31, 2023, we did not impair any of our hormone therapy drug patent assets. Our intangible assets subject to amortization are expected to be amortized as follows (in thousands):
Year ending December 31, |  |  |
2025 |  | $ | 384 |
2026 |  |  | 384 |
2027 |  |  | 384 |
2028 |  |  | 385 |
2029 |  |  | 384 |
Thereafter |  |  | 1,787 |
Total |  | $ | 3,708 |

X
- References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/985-20/tableOfContent + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration